Overexpression of Limb Bud and Heart Alleviates Sepsis-Induced Acute Lung Injury Via Inhibiting the NLRP3 Inflammasome
Overview
Biotechnology
General Medicine
Authors
Affiliations
Objective: Sepsis is a leading cause of acute lung injury (ALI). This study attempted to investigate the effects of limb bud and heart (LBH) on the development of sepsis-induced ALI and its underlying mechanism of action.
Methods: The sepsis-induced ALI mouse model was established by cecal ligation and puncture (CLP). The lung injury score and lung wet/dry weight (W/D) ratio were used to evaluate the lung injury. , ALI was simulated by lipopolysaccharide (LPS) treatment in A549 cells. The mRNA expression of LBH, NLRP3, ASC, and proinflammatory cytokines was measured by qRT-PCR. The viability of LPS-induced A549 cells was analyzed by MTT assay. Furthermore, western blot was performed to detect the protein expression of LBH, NLRP3, and ASC. LPS-induced A549 cells were treated with MCC950 (NLRP3 inflammasome inhibitor) to confirm the effect of LBH on NLRP3 inflammasome.
Results: The mRNA and protein expression of LBH was decreased in sepsis-induced ALI. LBH overexpression reduced the lung injury score, lung W/D ratio, expression of proinflammatory cytokines, and NLRP3 inflammasome activation in sepsis-induced ALI mouse model. Additionally, LBH upregulation increased the viability, while it decreased the proinflammatory cytokine expression and NLRP3 inflammasome activation of LPS-induced A549 cells. Moreover, MCC950 reversed the promoting effects of LBH silencing on proinflammatory cytokine expression and NLRP3 inflammasome activation in LPS-induced A549 cells.
Conclusions: LBH alleviated lung injury in sepsis-induced ALI mouse model by inhibiting inflammation and NLRP3 inflammasome, and restrained the inflammation by inhibiting NLRP3 inflammasome in LPS-induced A549 cells, providing a novel therapeutic target for ALI.
Glycyrrhizic Acid Protects Experimental Sepsis Rats against Acute Lung Injury and Inflammation.
Shen J, Hua Z, Chai Y Evid Based Complement Alternat Med. 2022; 2022:3571800.
PMID: 36072408 PMC: 9444394. DOI: 10.1155/2022/3571800.
Mohamed G, Ibrahim S, El-Agamy D, Elsaed W, Sirwi A, Asfour H Biology (Basel). 2021; 10(11).
PMID: 34827212 PMC: 8614783. DOI: 10.3390/biology10111219.